Viatris' (VTRS) China business remains resilient despite concerns over the country's new volume-cont

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

Viatris’ second-quarter results were met with a negative market reaction, despite the company surpassing Wall Street’s revenue and non-GAAP profit expectations. Management attributed the quarter’s performance to strong commercial execution in Greater China, where investments in established brands and e-commerce channels drove double-digit growth. CEO Scott Smith emphasized that demand for cardiovascular products and the company’s strategic focus on higher-margin generics in North America contrib

According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent […]

Greater China surges 16% as management raises full-year guidance.

Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.

Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year’s revenue to be around $14.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15% above analysts’ consensus estimates.

In early August 2026, Viatris Inc. reported higher second-quarter and year-to-date revenues, a six-month return to net profitability, raised its 2026 earnings guidance midpoint to US$14.75 billion, completed a US$1.15 billion share repurchase program covering 8.7% of shares, and affirmed a US$0.12 quarterly dividend. An interesting angle is that Viatris paired improved earnings and guidance with both capital returns and the FDA approval of its low-estrogen Gwyn Lo contraceptive patch,...

Viatris stock has delivered a strong 76.1% return over the past year, and the broader valuation checks still indicate the shares may be pricing in less than the company’s fundamentals could justify. Viatris is up 76.1% over the last 12 months, which puts more focus on whether the recent share price better reflects the company’s long term earnings power. Recent product news, including the FDA approval of the Gwyn Lo contraceptive patch and the agreement to transfer rights to TYRVAYA nasal...

Viatris raises 2026 guidance alongside completed buyback and fresh product approval Viatris (VTRS) has given investors a busy early August, pairing raised 2026 revenue guidance and completion of a multi year share repurchase program with new product news and an affirmed quarterly dividend. See our latest analysis for Viatris. The recent guidance lift, completion of a US$1.15b buyback and fresh product approval come after a strong run for Viatris, with a year to date share price return of...

The latest research on Viatris centers on a revised price target of US$22 per share and what that figure implies for investors following the story. Analysts are split, with more optimistic views pointing to execution on the product pipeline and cautious views questioning how fully the current stock price already reflects those expectations. As the article continues, you will see how this updated target fits into the evolving narrative around Viatris and how you can track the key signposts...

Viatris Inc (VTRS) delivers 3.5% operational revenue growth and raises full-year 2026 guidance, while navigating supply disruptions and competitive pressures.

Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.

Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Viatris (VTRS) delivered earnings and revenue surprises of +11.29% and +2.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year’s revenue to be around $14.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15% above analysts’ consensus estimates.

Beyond analysts' top-and-bottom-line estimates for Viatris (VTRS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing headwinds across parts of its portfolio.

Though Viatris has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of +105.26% and +4.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Viatris received U.S. FDA approval for its new combined hormonal contraceptive patch, Gwyn Lo. The product is a low dose estrogen contraceptive patch with data supporting efficacy and safety. This approval adds a fresh option to Viatris' women’s health portfolio and may influence its U.S. market position. For investors watching Viatris (NasdaqGS:VTRS), the Gwyn Lo approval comes at a time when the stock has shown strong momentum. The current share price of $17.56 comes alongside a 40.9%...

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with Viatris (NASDAQ:VTRS).

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 9.7% gain over the past six months, beating the S&P 500 by 1.8 percentage points.

Generic drugmakers face U.S. manufacturing deadlines as India and global suppliers weigh potential tariff impact.

Viatris is scheduled to report its second-quarter results next month, with Wall Street expecting earnings per share to remain roughly unchanged from a year ago.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

JPMorgan Chase stock and two other financial names hit new highs. A pharmaceutical stock also reached a high and is in a buy zone.

By Yantoultra Ngui SINGAPORE, July 13 (Reuters) - Mylan Inc, part of a global healthcare company Viatris, plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd, worth up to 34.81